CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 021330/S-014
NDA 022360/S-005

Name: Nicorette® Lozenge (nicotine polacrilex)

Sponsor: GlaxoSmithKline Consumer Healthcare, L.P.

Approval Date: March 8, 2013

These "Changes Being Effected in 30 Days" supplemental new drug applications provide for the addition of two analytical testing sites for evaluation of the drug product and storage of stability samples.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021330/S-014
NDA 022360/S-005

CONTENTS

Reviews / Information Included in this Review

Approval Letter	**X**
Approvable Letter	
Labeling	
Division Director's Memo	
Labeling Review(s)	
Medical Review(s)	
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology / Toxicology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology & Biopharmaceutics Review(s)	
Other Review(s)	
Administrative and Correspondence Documents	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021330/S-014

NDA 022360/S-005

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21330/ S-014 and 22360/ S-005

APPROVAL LETTER

GlaxoSmithKline Consumer Healthcare, L.P.
Attention: Iris H. Shelton, M.S., RAC
Associate Director, Regulatory Affairs
1500 Littleton Road,
Parsippany NJ 07054-3884

Dear Ms. Shelton

Please refer to your Supplemental New Drug Applications (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA	Supplement	Drug Product	Dated	Received
21330	014	Nicorette® Lozenge (nicotine polacrilex)	September 10, 2012	September 10, 2012
22360	005	Nicorette® (nicotine polacrilex)	September 27, 2012	September 27, 2012

These "Changes Being Effected in 30 Days" supplemental new drug applications provide for the addition of two analytical testing sites ((b) (4) (b) (4)) for evaluation of the drug product and storage of stability samples.

We have completed our review of these supplemental new drug applications. These supplements are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796-4013.

Sincerely,

{See appended electronic signature page}
Ramesh Raghavachari, Ph.D.
Branch Chief, Branch IX,
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
03/08/2013

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021330/S-014

NDA 022360/S-005

CHEMISTRY REVIEWS

NDA 21-330, S-014
NDA 22-360, S-005

DIVISION OF NEW DRUG QUALITY ASSESSMENT III
POST-MARKETING, BRANCH IX
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-330 **DATE REVIEWED:** 3/8/2013
NDA #: 22-360

OND: DNCE

REVIEW #: 1 **REVIEWER:** Donald N. Klein, Ph.D.

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE
N21-330 CBE-30	9/10/12	9/10/12
N22-360 CBE-30	9/27/12	9/27/12

NAME & ADDRESS OF APPLICANT:

GlaxoSmithKline Consumer Healthcare, L.P.
1500 Littleton Road
Parsippany, NJ 07054

DRUG PRODUCT NAME:

N21-330:

Proprietary: Nicorette® Lozenge
Established (1985): Nicotine Polacrilex, USP

N22-360:

Proprietary: Nicorette® Mini Lozenge
Established (1985): Nicotine Polacrilex, USP

PHARMACOL. CATEGORY/INDICATION: Reduction of withdrawal symptoms associated with quitting to smoke.

DOSAGE FORM:

N21-330: Lozenge

N22-360: Lozenge

STRENGTHS:

N21-330: 2 mg and 4 mg

N22-360: 2 mg and 4 mg

ROUTE OF ADMINISTRATION: Oral

Rx/OTC: OTC

SPECIAL PRODUCTS: __Yes **X** No.

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

N21-330 and N22-360:

Chemical Name: 2-Propenoic acid, 2-methyl-, polymer with diethenylbenzene, complex with (*S*)-3-(1-methyl-2-pyrrolidinyl)pyridine

Molecular Formula: $[(C_4H_6O_2)_x(C_{10}H_{10})_y](C_{10}H_{14}N_2)$

MW: *n/a*

CAS #: 96055-45-7

Chemical Structure:



SUPPLEMENT PROVIDES FOR: The addition of two analytical testing sites (FEI (b) (4) and FEI (b) (4) for evaluation of the drug product and storage of stability samples.

CONCLUSION: Recommend Approval.

CMC REVIEW:

MODULE 3: QUALITY

3.2.P DRUG PRODUCT [Nicorette® and Nicorette® Mini; Lozenge]:

3.2.P.2 PHARMACEUTICAL DEVELOPMENT [Nicorette® and Nicorette® Mini; Lozenge]:

3.2.P.2.2 Drug Product:

3.2.P.2.2.3 Physicochemical and Biological Properties:

Attachment A: Nanotechnology product evaluating questions:

1, This review contains new information added to the table below: _____Yes; _X_No Review date: _3/8/2013__
2) Are any nanoscale materials included in this application? (If yes, please proceed to the next questions.) Yes_____; No__**X**; Maybe (please specify)_____
3 a) What nanomaterial is included in the product? (Examples of this are listed as search terms in Attachment B.) _____ 3 b) What is the source of the nanomaterial?_____
4) Is the nanomaterial a reformulation of a previously approved product? Yes_____ No_____
5) What is the nanomaterial functionality? Carrier_____; Excipient_____; Packaging_____ API_____; Other_____ _____
6) Is the nanomaterial soluble (e.g., nanocrystal) or insoluble **(**e.g., gold nanoparticle**)** in an aqueous environment? Soluble _____; Insoluble_____
7) Was particle size or size range of the nanomaterial included in the application? Yes_____(Complete 8); No_____ (go to 9).
8) What is the reported particle size? Mean particle size_____ ; Size range distribution_____; Other_____
9) Please indicate the reason(s) why the particle size or size range was not provided: _____ _____
10) What other properties of the nanoparticle were reported in the application (See Attachment E)? _____
11) List all methods used to characterize the nanomaterial?_____ _____

3.2.P.3 MANUFACTURE [Nicorette® and Nicorette® Mini; Lozenge]:

3.2.P.3.1 Manufacturers:

a. These two sites are added to N21-330 and N22-360 to conduct drug product testing (Assay; Content Uniformity; and Dissolution) and stability testing of the drug product:

(b) (4) **FEI:** (b) (4)

(b) (4) **FEI:** (b) (4)

EVALUATION: Acceptable.

1. Based on Compliance's Overall Recommendation, the proposed change meets 21 CFR 314.70(c).

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Application:	NDA 21330/014	**Action Goal:**	
Stamp Date:	10-SEP-2012	**District Goal:**	03-FEB-2013
Regulatory:	10-MAR-2013		
Applicant:	GLAXOSMITHKLINE CONS	**Brand Name:**	Nicorette (nicotine polacrilex) lozenge
	1500 LITTLETON RD	**Estab. Name:**	
	PARSIPPANY, NJ 070543884	**Generic Name:**	NICOTINE POLACRILEX
Priority:	3S	**Product Number; Dosage Form; Ingredient; Strengths**	
Org. Code:	560	003; TROCHE; NICOTINE POLACRILEX; EQ 2MG BASE 001; TROCHE; NICOTINE POLACRILEX; EQ 2MG BASE 002; TROCHE; NICOTINE POLACRILEX; EQ 4MG BASE	

Application Comment: PAC-ATLS; BUNDLED WITH N22-360, S-005 (on 12-OCT-2012 by D. KLEIN () 3017961689)

FDA Contacts:	L. RIVERA	Project Manager	3017964013
	K. RAMAN	Team Leader	3017961739

Overall Recommendation:	ACCEPTABLE	on 08-MAR-2013	by T. GOOEN	(HFD-320)	3017963257
	PENDING	on 12-OCT-2012	by EES_PROD		

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Establishment: **CFN:** (b) (4) **FEI:** (b) (4)

DMF No: **AADA:**

Responsibilities: FINISHED DOSAGE OTHER TESTER

Establishment Comment: TESTING FOR NICOTINE LOZENGE ASSAY, CONTENT UNIFORMITY, AND DISSOLUTION (on 17-SEP-2012 by L. RIVERA () 3017964013)

Profile: CONTROL TESTING LABORATORY **OAI Status:** NONE

Milestone Name	Milestone Date	Request Type	Planned Completion	Decision	Creator
Comment				Reason	
SUBMITTED TO OC	12-OCT-2012				KLEIND
SUBMITTED TO DO	16-OCT-2012	GMP Inspection			STOCKM
ASSIGNED INSPECTION TO IB	28-FEB-2013	Product Specific			PFIGAROL
DO RECOMMENDATION	08-MAR-2013			ACCEPTABLE	PFIGAROL
INSPECTION OF (b) (4) CLASSIFIED NAI.				INSPECTION	
OC RECOMMENDATION	08-MAR-2013			ACCEPTABLE	TGOOEN
				DISTRICT RECOMMENDATION	

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Establishment: **CFN:** **FEI:** (b) (4)

(b) (4)

DMF No: **AADA:**

Responsibilities: FINISHED DOSAGE OTHER TESTER

Establishment Comment: TESTING FOR NICOTINE LOZENGE ASSAY, CONTENT UNIFORMITY, AND DISSOLUTION (on 19-OCT-2012 by M. STOCK (HFD-320) 3017964753)

Profile: CONTROL TESTING LABORATORY **OAI Status:** NONE

Milestone Name	Milestone Date	Request Type	Planned Completion	Decision	Creator
Comment				Reason	
SUBMITTED TO OC	12-OCT-2012				KLEIND
SUBMITTED TO DO	19-OCT-2012	Product Specific			STOCKM
ASSIGNED INSPECTION TO IB	15-JAN-2013	Product Specific			LTHOMAS
INSPECTION PERFORMED	(b) (4)		(b) (4)		TOMSS
INSPECTION PERFORMED	(b) (4)		(b) (4)		TOMSS
THE FIRM IS LISTED AS A CONTROL TESTING LABORATORY FOR NDA 21330/014. THE RECENT/INITIAL INSPECTION OF THE FIRM OCCURRED (b) (4) DID NOT RESULT IN THE ISSUANCE OF AN FDA-483, AND WAS CLASSIFIED NAI. THE FOLLOWING DISCUSSION ITEMS WERE ADDRESSED WITH FIRM MANAGEMENT: (b) (4) (b) (4) DISTRICT OFFICE IS RECOMMENDING THAT THIS APPLICATION BE APPROVED BASED UPON THE RESULTS OF THIS INSPECTION.					
DO RECOMMENDATION	22-FEB-2013			ACCEPTABLE	TOMSS
THE FIRM IS LISTED AS A CONTROL TESTING LABORATORY FOR NDA 21330/014. THE RECENT/INITIAL INSPECTION OF THE FIRM OCCURRED (b) (4) DID NOT RESULT IN THE ISSUANCE OF AN FDA-483, AND WAS CLASSIFIED NAI. THE FOLLOWING DISCUSSION ITEMS WERE ADDRESSED WITH FIRM MANAGEMENT: (b) (4) (b) (4) DISTRICT OFFICE IS RECOMMENDING THAT THIS APPLICATION BE APPROVED BASED UPON THE RESULTS OF THIS INSPECTION.				INSPECTION	
OC RECOMMENDATION	27-FEB-2013			ACCEPTABLE	STOCKM
				DISTRICT RECOMMENDATION	

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DONALD N KLEIN
03/08/2013
Approval Recommended; CBE-30 Due 3/10/13.

RAMESH RAGHAVACHARI
03/08/2013

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021330/S-014
NDA 022360/S-005

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21330/ S-14

CBE-30 SUPPLEMENT –
bACKNOWLEDGEMENT

GlaxoSmithKline Consumer Healthcare
Attention: Iris H. Shelton, M.S., RAC
Associate Director, Regulatory Affairs
1500 Littleton Road,
Parsippany NJ 07054-3884

Dear Ms. Shelton:

We have received your Supplemental New Drug Application (sNDA) submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

NDA NUMBER: 21330

SUPPLEMENT NUMBER: 14

PRODUCT NAME: Nicorette® (nicotine polacrilex) 2 mg and 4 mg Lozenges

DATE OF SUBMISSION: September 10, 2012

DATE OF RECEIPT: September 10, 2012

This supplemental application, submitted as a "Supplement – Prior Approval," accepted as a "Changes Being Effected in 30 days" provides for adding an analytical testing site.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on November 9, 2012 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be March 10, 2013.

Please cite the application number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Nonprescription Clinical Evaluation
5901-B Ammendale Road
Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

If you have questions, call me, at (301) 796- 4013.

Sincerely,

{See appended electronic signature page}

LCDR Luz. E. Rivera, Psy.D.
Regulatory Project Manager
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LUZ E RIVERA
09/21/2012